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BACKGROUND: Photodynamic therapy (PDT) is a promising adjuvant therapy in cancer treatment. However, cancers resistant to PDT,
mediated through the efflux of photosensitisers by means of P-glycoprotein or ATP-binding cassette transporter proteins, have been
reported. The DNA repair has also been suggested to be responsible for PDT resistance, but little is known about the repair
pathways and mechanisms involved. Therefore, this study aimed to investigate the possible function of six major DNA repair
mechanisms in glioma cells resistant to Photofrin-mediated PDT (Ph-PDT).
METHODS: The U87 glioma cells relatively resistant to Ph-PDT were obtained by recovering the viable cells 3h after PDT treatment.
The mRNA and protein expression levels of DNA repair genes were evaluated by quantitative real-time reverse transcription-
polymerase chain reaction and western blotting, respectively. Small-interfering RNA and chromatin-immunoprecipitation assays were
used to further examine the relationship between AlkB, an alkylation repair homologue 2 (Escherichia coli)( ALKBH2) and Ph-PDT
responsiveness, and transcription factors involved in ALKBH2 transcription.
RESULTS: The ALKBH2 of DNA damage reversal was significantly increased at both mRNA and protein levels from 30min to 48h post-
treatment with Ph-PDT. Conversely, down-regulating ALKBH2 expression enhances Ph-PDT efficiency. Furthermore, our data clearly
show for the first time that tumour protein (TP53) is directly involved by binding to the promoter of ALKBH2 in mediating Ph-PDT
resistance.
CONCLUSION: The DNA damage reversal mechanisms may have important functions in Ph-PDT resistance through the activation of
ALKBH2 by TP53.
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Glioblastoma multiforme is one of the most common tumours
affecting the brain and notoriously difficult to cure. It is because
glioma cells are particularly resistant to therapy and coupled with
the problem of the blood–brain barrier, and the susceptibility of
healthy brain tissue to damage during treatment, new adjuvant
therapies are clearly needed to tackle this treatment-resistant
tumour (Gerstner and Fine, 2007).
Photodynamic therapy (PDT) is an emerging adjuvant therapy
used in the treatment of different tumours (O’Connor et al, 2009).
The PDT has several advantages over traditional treatment
regimens. Compared with surgery and radiotherapy, PDT causes
less severe long-term morbidity with comparable treatment
outcomes (Nyst et al, 2009). It can also be the choice of
re-treatment in cases of recurrence and incomplete tumour
responses after standard therapies and/or PDT as PDT does not
compromise re-treatment effectiveness (Hornung et al, 1998).
The PDT uses the excitation of photosensitisers in tumour cells
by light to interact with the oxygen in tissues, thus reactive oxygen
species are produced to kill the tumour cells through apoptosis or
necrosis (Pervaiz, 2001). Photofrin is the most commonly used
photosensitiser, and Photofrin-mediated PDT (Ph-PDT) has
already been approved for the treatment of different solid tumours
by the US Food and Drug Administration (Biel, 2006). Clinical
trials using Photofrin to treat gliomas are being carried out, but
reports on glioma cell resistance to Ph-PDT in vitro or in vivo are
emerging (Adams et al, 1999; Ferrario et al, 2007). This situation is
also seen in head and neck dysplasia or cancer patients in which
some of them failed to respond, or only partially responded to
Ph-PDT (Stylli et al, 2004; Rigual et al, 2009). The underlying
cellular mechanisms leading to failure to respond to Ph-PDT are
not fully understood. Several proteins and signalling pathways,
such as activation of anti-apoptotic proteins, cellular antioxidant
defence mechanisms and efflux of photosensitisers by means of
P-glycoprotein or ATP-binding cassette transporter proteins have
been shown to have significant functions in cellular resistance to
Ph-PDT (Saczko et al, 2007a; Usuda et al, 2008, 2010; Zheng et al,
2008). The interactions of these different pathways and proteins
may enhance tumour cell proliferation and differentiation,
promote invasion and prevent apoptosis, leading to the decreased
cytotoxicity of Ph-PDT.
The DNA repair has been shown to reduce cell death caused by
different cancer therapies, including radiotherapy and chemo-
therapy using a platinum agent (Frosina, 2009; Fukushima et al,
2009). The Ph-PDT has also been reported to induce significant Received 29 March 2010; revised 17 June 2010; accepted 18 June 2010
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2004; Saczko et al, 2008). Although different mechanisms have
been suggested to explain the causes of resistance in Ph-PDT,
the function of DNA repair mechanisms has not been fully
investigated. Therefore, we carried out a series of experiments to
investigate the DNA repair mechanism(s) that may be responsible
for the survival of glioma cells after Ph-PDT. Specific genes
representative of the main DNA repair pathways in human beings
were examined. The six specific genes are (1) AlkB, alkylation
repair homologue 2 (Escherichia coli)( ALKBH2) of direct DNA
damage reversal; (2) APEX nuclease (multifunctional DNA repair
enzyme) 1 (APEX1) of base excision repair (BER), which removes
small base lesions; (3) X-ray repair complementing defective repair
in Chinese hamster cells 1 (XRCC1) of short-patch BER, which is
responsible for repairing single base damage; (4) excision repair
cross-complementing rodent repair deficiency, complementation
group 5 (ERCC5) of nucleotide excision repair (NER) that repairs
bulky, helix-distorting lesions NER; (5) RAD52 homologue
(Saccharomyces cerevisiae)( RAD52) of double-strand break repair
and (6) REV1 homologue (S. cerevisiae)( REV1) of trans-
lesion synthesis, which is a DNA damage tolerance machinery
(Christmann et al, 2003).
In this study, viable glioma cells recovered 3h after Ph-PDT
were considered as relatively resistant/less responsive to Ph-PDT.
The gene ALKBH2, involved in DNA damage reversal, was
significantly expressed in these cells for at least 24h after
Ph-PDT. Knockdown of ALKBH2 intensified the cytotoxic effect
of Photofrin, which implies that it confers resistance to Ph-PDT.
We also showed both mRNA and protein levels of ALKBH2 were
up-regulated. This up-regulation was due to the binding of the
transcription factor tumour protein (TP53) to one of the predicted
promoter regions of ALKBH2, a finding that has not been reported
before.
MATERIALS AND METHODS
Cell culture
The human glioblastoma U87 cell line was obtained from
American Type Culture Collection (Rockville, MD, USA). The
cells were maintained in Minimum Essential Medium Alpha
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% foetal
bovine serum (complete medium) and were grown in a humidified
atmosphere at 371C and 5% CO2.
Photosensitiser and photodynamic treatment
Photofrin was a generous gift from Axcan Pharma (Quebec,
Canada). Stock solution (2.5mgml
 1) was prepared in 5%
dextrose and kept at  201C until use. Cells (2 10
5) were seeded
onto 60mm culture dishes in complete medium and incubated
overnight. Cells were then incubated in serum-free medium
containing 1mgml
 1 Photofrin for at least 18h to achieve maximal
uptake before being illuminated (Ph-PDT) (Jiang et al, 2003;
Dysart and Patterson, 2005; Au et al, 2006). Light irradiation of
cells was carried out using a quartz-halogen lamp coupled with a
500nm long-pass filter. The energy fluence rate was 33.5mWcm
 2
at a wavelength of 630nm. The following controls were also
included in all experiments: cell cultures without Photofrin and
light irradiation (no treatment controls); without Photofrin, but
illuminated (light controls, LCs) and with Photofrin, but not
illuminated (dark controls, DCs). Three hours after light irrad-
iation, the cells were used directly for cell survival and alkaline
comet assays (for examining DNA damage) or allowed to recover
in complete medium for various times before being analysed by
(i) chromatin immunoprecipitation (ChIP), (ii) western blotting,
(iii) real-time quantitative reverse transcription-polymerase chain
reaction (RT–PCR) and (iv) alkaline comet assay (for examining
DNA repair).
Cell survival assay
Cell survival was determined using the trypan-blue exclusion
method. Cells were diluted 1:9 in 500ml phosphate-buffered saline
(PBS) and stained with trypan blue. They were then analysed using
an automated Vi-CELL cell viability analyser (Beckman Coulter,
Brea, CA, USA), which has linearity approximately from 5 10
4 to
41 10
7cellsml
 1 (Szabo et al, 2004). The number of viable cells
in 50 images was counted and three replicates were performed on
each sample.
Alkaline comet assay
The assay was performed according to an earlier described
procedure (Collins et al, 1997). In brief, 4 10
4 cells were mixed
with 60ml of 1% low melting point agarose in PBS (371C) and
embedded on an agarose pre-treated standard microscope slide.
The slides were then immersed in lysis buffer for 1h to denature
the cellular proteins and then transferred to the alkaline
electrophoresis buffer and incubated for 30min at 41C in the dark
for DNA unwinding. Electrophoresis was then conducted for
30min at 25V and 300mA. Slides were neutralised with three
changes of 0.4M Tris–HCl buffer, pH 7.5, for 5min each and
stained with 30ml ethidium bromide (20mgml
 1). Individual
comets were viewed at a final magnification of  400 using a
fluorescence microscope (Eclipse E600, Nikon, Tokyo, Japan)
equipped with 590nm long-pass emission filter. Comets from two
slides of each sample were analysed using the Komet 5.5 software
(Kinetic imaging, Liverpool, UK) and 150 individual comets were
counted.
Real-time quantitative RT–PCR
Total RNA was isolated using PureLink Micro-to-Midi Total RNA
Purification kit (Invitrogen), and reverse transcribed using RevertAid
First Strand cDNA Synthesis kit (Fermentas, Ontario, Canada) with
oligo-dT primers according to the manufacturers’ protocols. To
analyse the relative gene expression, cDNA was then subjected to
TaqMan-based real-time quantitative PCR in a 7500 Real-Time PCR
system (Applied Biosystems, Foster City, CA, USA). Briefly, 7.5ng of
cDNA were added to 20mlo fP C Rm i xc o n t a i n i n g1  Universal PCR
Master Mix and 1ml validated TaqMan gene expression assay mix
(Applied Biosystems) for each gene shown in Table 1. The
amplification was carried out as follows: 1 cycle for denaturation
(951C per 10min) followed by 40 cycles for two-stage PCR (951Cp e r
15s and 601C per 1min). Fluorescence signals were measured
continuously during the repetitive cycles. The relative changes in gene
expression were calculated based on the 2
 DDCt method (Livak and
Schmittgen, 2001).
Western blotting
Cells were collected, washed in ice-cold PBS and lysed in WCE
buffer (20mM HEPES, 1mM EDTA, 1mM EGTA, 0.2M NaCl, 0.5%
Triton X-100, 10% glycerol and complete mini protease inhibitor
cocktail tablet (Roche, Branchburg, NJ, USA)). The lysates were
boiled in SDS sample buffer (62.5mM Tris–HCl (pH 6.8), 1%
b-mercaptoethanol, 10% glycerol, 1% SDS and 0.001% bromophenol
blue) and separated by 10% SDS–PAGE. The separated proteins
were then blotted onto PVDF membranes (Amersham Biosciences,
Uppsala, Sweden) and blocked with 5% non-fat milk or 5% bovine
serum albumin (for Phospho-p53 antibody) in Tris-buffered saline
(pH 7.4) containing 0.1% Tween 20 for 1h at room temperature.
To examine different protein expression, the membranes were
probed with antibodies against ALKBH2 (1:1000 dilution, Abcam,
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(1:1000 dilution), p53 (1:200 dilution, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), Phospho-p53 (Ser-15) (1:1000 dilution, Cell
Signaling Technology, Beverly, MA, USA) and b-actin (1:2000
dilution, Santa Cruz Biotechnology). Corresponding horseradish
peroxidase-labelled anti-rabbit and anti-mouse antibodies were
used as secondary antibodies (Cell Signaling Technology). The
final complexes were visualised by enhanced chemiluminescence
autoradiography (Perkin Elmer, Cambridge, MA, USA).
Small-interfering RNA transfection
Fifty per cent confluent density of U87 glioma cells (1   10
5) were
seeded onto 35mm dishes in complete medium and incubated
overnight. Small-interfering RNA (siRNA) oligomers and Lipofec-
tamine 2000 transfection reagent (100pmol and 1:50 dilution,
respectively, Invitrogen) were mixed with serum-free medium,
incubated and added to each dish. In mock controls, the negative
control RNA was used instead of siRNA to act as a control. Cells
incubated with Lipofectamine alone were used as reagent control.
After 6h of incubation, the cells were recovered in complete
medium for 16h. They were then subjected to Ph-PDT treatment
as described above. Three hours after light irradiation, cells were
analysed by real-time quantitative RT–PCR, western blotting and
cell survival assay.
Chromatin immunoprecipitation
The U87 glioma cells were allowed to recover for 6h after Ph-PDT.
They were then cross-linked by formaldehyde (1% final concen-
tration) at room temperature for 10min. The fixation was
quenched by the addition of glycine at a final concentration of
0.125M. The cells were washed with cold PBS containing protease
inhibitors (Roche) and collected by scraping. The ChIP was
performed using the MAGnify chromatin-immunoprecipitation
system (Invitrogen) according to the manufacturer’s protocol.
Briefly, the cells were lysed and chromatin was released from the
nuclei. Chromatin was sheared to around 200 to 500bp fragment
sizes by sonication. The cross-linked protein–protein and
protein–DNA fragments were immunoprecipitated by anti-TP53
or anti-IgG antibodies conjugated to Dynabeads Protein A/G. The
cross-linking was reversed by heat treatment, and DNA associated
with TP53 was isolated by DNA purification magnetic beads.
The isolated DNA was analysed by both conventional and real-time
PCR.
PCR analysis for ChIP
The primers (Table 2) for conventional and SYBR green real-time
quantitative PCR were designed from Homo sapiens chromosome
12 reference complement sequence (accession no: NC_000012.10)
using the Oligo program version 6.57 (Molecular Biology Insights,
Cascade, CO, USA). In conventional PCR, 5ml of each DNA sample
from ChIP assay were mixed with 25ml of PCR master mix
containing 1X GeneAmp PCR Gold Buffer, 0.2mM of each dNTP,
2.5mM MgCl2, 0.3mM of each primer and 0.5U AmpliTaq Gold
DNA polymerase (Applied Biosystems). The amplification cycle
was carried out as follows: 1 cycle for denaturation (951C per
5min) followed by 30 cycles for amplification (951C per 15s, 551C
per 1min and 721C per 1min) and final extension of 10min at
721C. The PCR products were subjected to agarose gel electro-
phoresis for examination. In real-time quantitative PCR using
SYBR green, 5ml of each DNA sample were mixed with 25mlo f
PCR mix containing Maxima SYBR Green/ROX qPCR Master Mix
(Fermentas) and 0.3mM of each primer. The amplification cycle
used was as follows: 1 cycle for denaturation (951C per 10min)
followed by 40 cycles for amplification (951C per 15s and 601C per
1min). Fluorescence signals were measured continuously during
the repetitive cycles with an Applied Biosystems 7500 Real-Time
PCR system. The relative changes in gene expression were
calculated based on the 2
 DDCt method.
Statistics
Data are presented as meanþs.d. Statistical significance for
differences was determined by paired t-test, one-way ANOVA
with Tukey’s post-test and two-way ANOVA with Bonferroni’s
post-test.
RESULTS
Photofrin-mediated photodynamic treatment causes
DNA damage
The U87 glioma cells without Photofrin treatment were exposed
to different light doses, namely control (CNT) at 0Jcm
 2,L C1a t
0.8Jcm
 2 and LC 2 at 1.3Jcm
 2, respectively. The mean DNA
Table 2 The primers used in conventional and real-time quantitative PCR for ChIP analysis
Primers Sequences (50 to 30) Positions Applications
(1) p53_F1 TGCTCCCACTCGTGACAATA  257 to  238 Used in conventional PCR and real-time PCR of position 1 p53-binding site.
(2) p53_R2 GCCACTGTCGAGAATCAC  138 to  155 Used in real-time PCR of position 1 p53-binding site only.
(3) p53_F2 CAGCCGTGATTCTCGACA  143 to  160 Used in real-time PCR of position 2 p53-binding site only.
(4) p53_R1 AACCGCACGCAAAATTCTGATAT +147 to +125 Used in conventional PCR and real-time PCR of position 2 p53-binding site.
Abbreviations: ChIP¼chromatin immunoprecipitation; PCR¼polymerase chain reaction.
Table 1 The validated TaqMan gene expression assays
Primers Assay ID Interrogated sequence Exon boundary Assay location Amplicon length (bp)
(1) ALKBH2 Hs00419572_m1 NM_001001655.1 2–3 478 86
(2) REV1 Hs00249411_m1 NM_001037872.1 2–3 268 63
(3) RAD52 Hs00172536_m1 NM_134424.2 2–3 197 65
(4) APEX1 Hs00172396_m1 NM_080648.1 3–4 510 81
(5) XRCC1 Hs00959834_m1 NM_006297.2 4–5 536 75
(6) ERCC5 Hs00164482_m1 NM_000123.2 14–15 3407 118
Adapted and modified from http://www.appliedbiosystems.com.hk/
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spercentage in comet tails of LCs (B2%) was not significantly
different from CNT (Figure 1). When cells were treated with
Photofrin (1mgml
 1) and exposed to different light doses (DC at
0Jcm
 2, lethal dose (LD) 10 at 0.8Jcm
 2 and LD 40 at 1.3Jcm
 2),
there was significant DNA damage as the mean DNA percentage in
comet tails increased 3h (black bars in Figure 1) after light
irradiation (8.1% in DC, 13.9% in LD 10 and 33.2% in LD 40; all
Po0.001 when compared with that of CNT). Photofrin alone
caused DNA damage and light activation caused further DNA
damage in a light dose-dependent manner.
Involvement of DNA repair in relatively resistant glioma
cells after recovery from Ph-PDT
To determine whether there was any DNA repair in the relatively
resistant glioma cells that survived Ph-PDT, DNA damage was
evaluated after the cells had been allowed to recover for 24h. There
was no significant change in the mean DNA percentage in comet
tails of CNT and LCs. In contrast, the mean DNA percentage of
DC (3.3%), LD 10 (10.3%) and LD 40 (20.3%) were reduced
considerably when compared with those cells that had recovered
for 3h only (white bars compared with black bars in Figure 1).
ALKBH2 expression increases significantly after recovery
from Ph-PDT
The involvement of the six selected DNA repair pathways were
evaluated by determining the relative mRNA expression levels
( DDCt) of their target DNA repair genes in the less responsive
glioma cells, that is surviving cells after Ph-PDT, 48h after
treatment. Most of the target genes were expressed equally in both
control and treated cells (Figure 2A). However, ALKBH2 and REV1
were significantly over-expressed in those LD 10 and LD 40
recovering cells by approximately 3- and 1.4-fold, respectively,
when compared with the controls (Po0.01). Corresponding
increased protein levels of ALKBH2 were observed (Figure 2B),
but not in REV1 (data not shown). The kinetics of ALKBH2
gene expression was further investigated by quantitative RT–PCR.
The mRNA level was evidently induced from 0.5h and remained
high at 12h (Figure 2C). The corresponding ALKBH2 protein
was also elevated in a time-dependent manner (Figure 2D).
Up-regulation of ALKBH2 at the protein level, but not at the RNA
level, was found in DC group. Increase in ALKBH2 translation in
DC group may be due to the small amount of DNA damage
induced by the dark toxicity of Photofrin (see Figure 1).
Knockdown of ALKBH2 significantly increases the
cytotoxicity of Ph-PDT
Compared with the control cells (transfected with Lipofectamine
alone or negative control RNA), siALKBH2 cells had much reduced
ALKBH2 protein expression (Figure 3A). The sensitivity of these
cells to Photofrin was more than those of the control cells,
resulting in more cell deaths after light irradiation (Figure 3B). The
sensitising effect was more evident with increasing light doses,
with a cytotoxicity at B8% at low light dose (0.8Jcm
 2) and
increased to B25% at high light dose (1.3Jcm
 2). The cytotoxicity
levels did not reach the respective LD 10 and LD 40 levels because
the uptake of Photofrin was reduced in the presence of
Lipofectamine (data not shown).
Ph-PDT increases the expression of TP53 transcription
factor and its activated phosphorylated form – p-TP53
To investigate the induction of ALKBH2 gene expression under
Ph-PDT condition, transcription factor-binding sites on ALKBH2
were predicted and assessed. According to the Transcription
Element Search System (TESS) web tool (http://www.cbil.upenn.
edu/cgi-bin/tess/tess?RQ¼WELCOME), TP53 is one of the
potential-binding transcription factors. Its function in Ph-PDT
was first examined by RT–PCR and western blotting. The mRNA
and protein expression of TP53 in U87 glioma cells were shown
to be increased 0.5h after PDT (Figure 4A). The protein expression
was maximal at 0.5 and 3.5h. The level of p-TP53, which is
associated with DNA repair mechanisms, was also shown to
increase from 3.5 to 12.5h in PDT-treated glioma cells.
Increased TP53 binding on ALKBH2 after Ph-PDT
treatment
To show whether TP53 is involved directly, through binding as a
transcription factor, in the transcription of ALKBH2 induced by
Ph-PDT, the ChIP assay was used. Figure 4B clearly shows that
TP53 binds to ALKBH2 gene, as there was a PCR product in the
TP53-immunoprecipitated sample of Ph-PDT-treated cells. Two
TP53-binding sites (approximately  190bp and  14bp; þ1i s
transcription start site) were predicted by TESS. Real-time PCR
was used to determine the binding position of TP53 on ALKBH2
promoter sequence. Figure 4C confirms TP53 binding to ALKBH2
as well as indicating its binding location at  190bp (4.5-fold
increase), but not at the  14bp region.
DISCUSSION
Numerous studies have shown that Ph-PDT induces significant
DNA damage (Woods et al, 2004; Saczko et al, 2008). Different
types of DNA damage may be seen, including double-strand
breaks, single-strand breaks, DNA base oxidation and cross-links
(Nowis et al, 2005). As DNA damage is not directly linked to the
cell death caused by PDT, little research has been conducted to
investigate the involvement of DNA repair in PDT. However,
Penning et al (1994) showed that the inhibition of a DNA repair
enzyme (poly(ADP-ribose)polymerase) activity and the formation
of irreversible DNA damage were correlated to the killing effect of
hematoporphyrin derivative PDT in a murine fibroblast cell line;
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Figure 1 The DNA damage and repair in U87 glioma cells after
Photofrin-mediated PDT; DNA damage was detected by the alkaline
comet assay and quantified as DNA percentage in tail. Cells were collected
3h (black bars) and 24h (white bars) after Ph-PDT. Cells treated with
Photofrin (1mgml
 1) alone (DC) or Photofrin-mediated PDT at 0.8 and
1.3Jcm
 2 light doses, that is lethal dose 10 and 40 (LD 10 and LD 40),
were significantly damaged when compared with the untreated control
(CNT) and cells exposed to 0.8 and 1.3Jcm
 2 light doses only (LC1 and
LC2). Twenty-four hours after treatment, the DNA damages in DC, LD 10
and LD 40 were significantly repaired. Data obtained from three
independent experiments are expressed as meanþs.d. and analysed using
paired t-test (***Po0.001).
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Figure 2 Photofrin-mediated PDT induces DNA repair gene expression. (A) Quantitative real-time RT–PCR of DNA repair genes at 48h after
Photofrin-mediated PDT. ALKBH2 and REV1 were significantly expressed in LD10 and LD 40; DC is used as reference sample and CNT is used to examine
the background expression levels of different DNA repair genes in U87 glioma cells. Data are expressed as meanþs.d. and analysed using one-way ANOVA
with Tukey’s multiple comparison post-test of three independent experiments (**Po0.01). (B) Increased ALKBH2 protein levels in glioma cells at 48h after
Ph-PDT. (C) Quantitative real-time RT–PCR showed significant ALKBH2 gene expression at different time points after Photofrin-mediated PDT at LD 10.
The mRNA level was significantly increased when compared with that of CNT and DC. Data are expressed as meanþs.d. and analysed using two-way
ANOVA with Bonferroni’s post-test of three independent experiments (*** represents the whole curve of LD 10 group is significant compared with both
DC and CNT with Po 0.001 at 0.5, 3.5 and 12.5h and Po0.01 at 6.5 and 9.5h). (D) Protein expression of ALKBH2 at different time points after Photofrin-
mediated PDT treatment at LD 10.
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snote that Photofrin is purified form of hematoporphyrin
derivative. They suggested that the involvement of DNA damage
and repair in PDT is cell-type dependent. Another study by Gupta
et al (2003) illustrated that enhanced DNA repair lowered the
micronuclei frequencies and thus increased the relative resistance
to PDT. The DNA repair capacity is determined not only by cell
type, but also the oxygen concentration and subcellular locali-
sation of Photofrin. As glioma treatment using Ph-PDT is under
clinical trial, the detailed DNA repair mechanism involved should
be studied, so that the efficacy of Ph-PDT can be enhanced
by preventing DNA repair-induced resistance.
On the basis of the knowledge gained from the studies
mentioned above, our preliminary focus was to examine the
participation of DNA damage and repair in a glioma cell line after
Ph-PDT. Our results were consistent with other reports in that the
amount of DNA damage is positively associated with PDT light
dosage (Woods et al, 2004). The DNA damage is increased in
Ph-PDT treatment groups (LD 10 and LD 40) when the PDT light
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expression in cells transfected with Lipofectamine alone or with the antisense oligonucleotide (siRNA) for ALKBH2 gene knockdown or unrelated
oligonucleotide as negative control (Neg CNT). (B) Survival rate (%) of cells treated with Lipofectamine alone (Lipofectamine) (dashed line with squares),
siRNA (triangles) and Neg CNT (circles) was assessed using the trypan-blue assay. Cells were exposed to different light doses alone (left panel) or treated
with Ph-PDT (right panel). Both protein expression and survival rate were examined 3h after Ph-PDT. Data are expressed as mean±s.d. and analysed using
one-way ANOVA with Tukey’s multiple comparison post-test of three independent experiments (***Po0.001).
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sdose was increased (Figure 1). The DNA damage in treatment
groups are significantly different from the glioma cells treated with
light only (LCs) and with Photofrin only (DC). It is clear from the
results presented here that light only will not cause significant
DNA damage. In the DC, DNA was damaged to a lesser extent
when compared with the PDT-treated groups. The DNA damage
in the DC may be due to the low dose of light coming from
ambient lighting that affected the cells during the course of the
experiments. As Photofrin is not localised in the nucleus to cause
DNA damage, the increase of DNA damage in PDT-treated groups
may be explained by the impairment of the nuclear membrane
after light irradiation (Moan et al, 1990; Saczko et al, 2007b).
Consequently, sensitised reactive molecules, including photo-
products, can enter the nucleus and damage DNA (Evensen and
Moan, 1982).
The DNA repair efficiency was less effective in the low light dose
(LD 10) treatment group than that in the high light dose (LD 40)
group. As the DNA repair capacity of the cells should be the same,
the difference in the efficiency may be resulted from different DNA
repair kinetics being activated by different light doses. Although
DNA damage was also found in DCs, the damage was completely
repaired after 24h. This may be due to the small amounts of DNA
damage present in the DC cells, but the participation of another
DNA repair kinetics cannot be excluded. As our data indicate that
DNA repair mechanisms are triggered in the relatively resistant
U87 glioma cells after 48h of recovery from Ph-PDT, we used real-
time quantitative RT–PCR to determine which DNA repair gene(s)
might be involved. The expression of the ALKBH2 gene of DNA
damage reversal and, to a much lesser extent, the REV1 gene of
translesion synthesis were found to be induced (Figure 2). The
results indicate that both DNA damage reversal and translesion
synthesis mechanisms may have important functions in glioma
cells resistant to Ph-PDT. The REV1 gene is involved in translesion
synthesis, and allows damaged DNA to be tolerated by replicative
bypass. When translesion synthesis is triggered, DNA replicates
with mutations or errors and thus DNA damage-induced muta-
genesis occurs (Prakash et al, 2005). As ALKBH2 is more
significantly expressed in the relatively resistant glioma cells, we
focused on the molecular process leading to induction of ALKBH2
expression during Ph-PDT and its contribution to PDT resistance.
The ALKBH2 gene is not significantly expressed in normal
brain cells, but high levels are found in liver tissue and sexual
organs (Duncan et al, 2002; Lee et al, 2005). It is responsible for
repairing 1-methyladenine (1meA), 3-methylcytosine (3meC) and
1,N
6-ethenoadenine (eA) on double-stranded DNA by oxidative
demethylation (Lee et al, 2005; Ringvoll et al, 2008). Cetica et al
(2009) showed that ALKBH2 is highly expressed in gliomas and
suggested that this aberrant expression has a part in tumour cell
resistance to cancer treatments. We also found an up-regulation of
ALKBH2 in glioma cells from 30min to 48h post-treatment with
Ph-PDT. This observation may imply that the photosensitised
reactive products in Ph-PDT produce 1meA, 3meC and/or eAo n
DNA. Most DNA damage studies of Ph-PDT target DNA damage
caused by oxidation. Here, we suggest that the photosensitised
reactive products may also cause DNA methylation and lipid
peroxidation to produce methylated DNA damage and etheno-
adenine DNA lesions, respectively. Prolonged high expression of
ALKBH2 also indicates that it may modulate the responsiveness to
Ph-PDT. To confirm a specific function of ALKBH2 in affecting
Ph-PDT response, we used a gene-knockdown approach. As
illustrated in Figure 3, cytotoxicity of Ph-PDT is enhanced after
silencing the ALKBH2 gene. This is the first report to show that the
expression of ALKBH2 in glioma cells correlates to Ph-PDT
resistance and DNA damage reversal.
The transcription factors involved in the transcription of
ALKBH2 remain unknown. However, we have shown increased
TP53 binding on the ALKBH2 promoter region, and the levels of
TP53 and p-TP53 were rapidly increased after Ph-PDT. Therefore,
TP53 appears to be critical in the regulation of ALKBH2 gene
expression. There is some evidence that TP53 is involved in PDT,
but its exact function in cellular responsiveness is controversial.
Mikes et al (2009) reported that TP53-dependent apoptosis affects
PDT efficacy. The investigators showed that adenocarcinoma colon
cancer cells expressing wild-type TP53 have lower clonogenic
efficiency than the TP53-deficient cells after Hypericin-mediated
PDT. This may be due to a higher incidence of apoptosis caused by
up-regulation of TP53 expression leading to the expression of pro-
apoptotic proteins. However, TP53 may also confer PDT resistance
to cells, possibly through DNA repair mechanisms, as cells allowed
to recover for 24h had similar clonogenic potential as the TP53-
deficient cells. Using another photosensitiser, m-THPC, Heinzel-
mann-Schwarz et al (2003) showed that TP53 is required for
apoptosis and interacts with the DNA repair gene Ataxia
Telangiectasia Mutated to have a function in apoptosis as well as
in responding to DNA damage induced by m-THPC-PDT. Our
results are in agreement with these studies and clearly show that
TP53 is involved in Ph-PDT. Up-regulation of p-TP53 at Ser-15 is
indicative of DNA damage (Maya et al, 2001), thus, DNA repair has
an important function in Ph-PDT resistance.
Some in vitro studies on human colon carcinoma, immortalised
Li–Fraumeni syndrome and promyelocytic leukaemia found that
the cell lines with mutant TP53 have lower sensitivity to Ph-PDT
than those with wild-type TP53. This may be due to a decrease in
TP53-dependent apoptosis after Ph-PDT (Tong et al, 2000).
However, Evans et al (1997) found that Ph-PDT-induced apoptosis
was higher in the lymphoblastic cell line with mutant TP53 than
that with wild-type TP53, although the cytotoxic effect of Ph-PDT
on both cell lines were not different. Another important finding by
the same group was that the mutagenicity induced by Ph-PDT in
the cell line with mutant TP53 was higher. Therefore, the
relationship between TP53 and Ph-PDT responsiveness seems to
be cell-type dependent. As different glioma cell lines may possess
different TP53 status as well as other genetic differences, the effect
of TP53 and ALKBH2 on the efficacy of Ph-PDT should be
compared with other cell lines. In our case, the U87 glioma cell line
has wild-type TP53 and it may be involved in conferring resistance
to these cells against Ph-PDT through the activation of ALKBH2
DNA repair gene. Hence, our findings will further gain knowledge
on how to improve the efficacy of Ph-PDT on gliomas by inhibiting
the expression of ALKBH2. Further research is required to
elucidate the function of TP53 and other regulators in controlling
ALKBH2 expression after Ph-PDT.
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